CCND1 and neoplasm: 5‐HT1BR activated by 5‐HT activates the MAPK/ERK pathway, EF‐2 kinase, the cyclin D1 pathway and α‐smooth muscle antigen; inhibits the caspase pathway; and inhibits apoptosis in tumor cells.